1. Home
  2. PNW vs CYTK Comparison

PNW vs CYTK Comparison

Compare PNW & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pinnacle West Capital Corporation

PNW

Pinnacle West Capital Corporation

SELL

Current Price

$101.63

Market Cap

11.1B

Sector

Utilities

ML Signal

SELL

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

SELL

Current Price

$64.21

Market Cap

10.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PNW
CYTK
Founded
1985
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1B
10.7B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
PNW
CYTK
Price
$101.63
$64.21
Analyst Decision
Hold
Buy
Analyst Count
17
22
Target Price
$102.93
★ $109.40
AVG Volume (30 Days)
990.9K
★ 2.0M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
★ 3.57%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.70
N/A
Revenue
★ $5,339,939,000.00
$13,368,000.00
Revenue This Year
$5.16
$72.47
Revenue Next Year
$5.71
$179.45
P/E Ratio
$60.06
★ N/A
Revenue Growth
★ 4.20
N/A
52 Week Low
$86.18
$54.30
52 Week High
$111.16
$88.31

Technical Indicators

Market Signals
Indicator
PNW
CYTK
Relative Strength Index (RSI) 69.63 43.08
Support Level $97.26 $63.96
Resistance Level $103.70 $67.07
Average True Range (ATR) 1.82 1.99
MACD 1.02 0.33
Stochastic Oscillator 85.12 61.26

Price Performance

Historical Comparison
PNW
CYTK

About PNW Pinnacle West Capital Corporation

Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: